Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CorMedix Conference Call

|Includes: CorMedix Inc. (CRMD)

This one might be worth listening to. The company has an approved product for sale in EU and is currently in discussions with FDA for a U.S. trial. Product is both safe and efficacious. Sales tem in EU has big pharma experience and has expertise in the dialysis space. IP issue is cloudy in EU but recent ruling(Prosl patent) should strengthen CRMD's hand. Short term catalysts include organic sales , likely partnering outside of EU(Middle East or Asia) and announcements re: approval of U.S. trial design. Longer term IP issue could also provide significant upside as existing provider is likely infringing on IP (see CorMedix S-1 for details).

Please note that this issuer is not followed on the Street and remains quite illiquid. That said, valuation is exceptionally low in light of approved product status and potential market size of indications(dialysis, oncology, etc. ) for same. This is also a natural fit for the big two in U.S. dialysis space(Fresenius, DaVita) Long here and quite, quite hopeful.

CorMedix to Report Third Quarter Financial Results on November 19, 2013

BRIDGEWATER, N.J., Nov. 15, 2013 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the Company will report financial results for the third quarter ended September 30, 2013 after the close of trading on Tuesday, November 19, 2013. CorMedix has filed form 12b-25 with the U.S. Securities and Exchange Commission (the "SEC"), and as a result, the deadline for the Company to file its quarterly report on Form 10-Q with the SEC has been extended to November 19, 2013. CorMedix management will hold a conference call on Wednesday, November 20, 2013, at 9a.m. EST to discuss the results and provide an update on recent business developments. To access the call, please dial 1-866-866-1333 in the United States, and 1-404-260-1421 internationally. A live webcast of the conference call will also be available on the investor relations page of the Company's website at

Disclosure: I am long CRMD.